Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BYSI 
BeyondSpring Inc (BYSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: BYSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.25
1 Year Target Price $1.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.85% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 83.08M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 1 | Beta 0.53 | 52 Weeks Range 0.98 - 3.44 | Updated Date 11/14/2025 |
52 Weeks Range 0.98 - 3.44 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.74% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 74961318 | Price to Sales(TTM) 31.22 |
Enterprise Value 74961318 | Price to Sales(TTM) 31.22 | ||
Enterprise Value to Revenue 26.53 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40332320 | Shares Floating 30674746 |
Shares Outstanding 40332320 | Shares Floating 30674746 | ||
Percent Insiders 15.26 | Percent Institutions 14.35 |
Upturn AI SWOT
BeyondSpring Inc
Company Overview
History and Background
BeyondSpring Inc., founded in 2010, is a global biopharmaceutical company focused on developing innovative cancer therapies. Initially focused on research and development, it has transitioned to late-stage clinical trials and regulatory submissions. The company's primary focus has been on its lead asset, Plinabulin.
Core Business Areas
- Drug Development: Research, development, and commercialization of cancer therapies, particularly Plinabulin.
Leadership and Structure
Dr. Lan Huang is the Co-Founder, CEO, and Chairman of BeyondSpring Inc. The company operates with a structure common to biopharmaceutical companies, emphasizing research, clinical development, regulatory affairs, and commercialization planning. In May 2024, Dr. Huang resigned as a director but continues as CEO and Chairman.
Top Products and Market Share
Key Offerings
- Plinabulin: Plinabulin is BeyondSpring's lead drug candidate, a selective guanine nucleotide exchange factor (GEF)-CD122 binding agonist for cancer therapy. It's designed to prevent chemotherapy-induced neutropenia (CIN) and has potential in cancer treatment. While it has been approved in China for CIN, it has faced regulatory challenges in the US. Competitors include Neulasta (pegfilgrastim) from Amgen (AMGN) and Granix (filgrastim) from Teva (TEVA). Market share and specific revenue data is not publicly available given limited approvals. However, the CIN market is significant, estimated to be in the billions of dollars annually.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The oncology segment is a significant and growing area within this industry.
Positioning
BeyondSpring is a clinical-stage biopharmaceutical company focused on cancer therapies. Its competitive advantage hinges on the success and differentiation of Plinabulin. The firm's pipeline consists solely of Plinabulin.
Total Addressable Market (TAM)
The total addressable market for cancer therapies and chemotherapy-induced neutropenia is significant, estimated at billions of dollars. BeyondSpring aims to capture a portion of this market with Plinabulin. Given competition from established products like Neulasta, BeyondSpring's positioning depends on demonstrating superiority or addressing unmet needs, as well as future pipeline development.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action of Plinabulin
- Potential to address unmet needs in CIN and cancer treatment
- Approved in China
Weaknesses
- Limited Product Portfolio (reliance on Plinabulin)
- Regulatory hurdles in key markets (e.g., US FDA)
- Financial constraints common to clinical-stage biopharmaceutical companies
Opportunities
- Expansion of Plinabulin's indications
- Potential partnerships for development and commercialization
- Further clinical trial success
Threats
- Regulatory setbacks
- Competition from established therapies
- Clinical trial failures
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- AMGN
- TEVA
- NVS
Competitive Landscape
BeyondSpring faces intense competition from established pharmaceutical companies with approved products and greater resources. Its success hinges on demonstrating a superior clinical profile for Plinabulin or addressing niche markets where existing therapies are inadequate.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of Plinabulin through clinical trials. Revenue growth is limited until product approval and commercialization.
Future Projections: Future projections depend heavily on the regulatory success and commercial uptake of Plinabulin. Analyst estimates would vary based on these factors.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for Plinabulin in various markets and exploring its potential in new cancer indications.
Summary
BeyondSpring is a high-risk, high-reward clinical-stage biopharmaceutical company primarily focused on Plinabulin. Its success is tied to the regulatory approval and market acceptance of its lead drug. The company's financial stability and future growth are dependent on its ability to secure further funding or partnerships. Investors should be aware of regulatory and financial uncertainties, the success of plinabulin and other competing therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BeyondSpring Inc. SEC Filings (10K, 10Q)
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://beyondspringpharma.com |
Full time employees 40 | Website https://beyondspringpharma.com | ||
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.